Frontline Ph-Negative B-cell Precursor Acute Lymphoblastic Leukemia Treatment and the Emerging Role of Blinatumomab

Authors

Elias J Jabbour
Hagop M Kantarjian
Nicola Goekbuget
Bijal D Shah
Sabina Chiaretti
Jae H Park
Anita W Rijneveld
Lia Gore
Shaun Fleming
Aaron C Logan
Josep M Ribera
Tobias F Menne
Khalid Mezzi
Faraz Zaman
Kelly Velasco
Nicolas Boissel

Publication Date

11-19-2024

Journal

Blood Cancer Journal

Abstract

This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.

Keywords

Humans, Antibodies, Bispecific, Philadelphia Chromosome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

DOI

10.1038/s41408-024-01179-4

PMID

39562780

PMCID

PMC11577064

PubMedCentral® Posted Date

11-19-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes